Fig. 8
A hypothetic model depicting the dual regulation mechanism of AGPS protein degradation by MDM2 and TrkA inhibitor. MDM2 ubiquitinates and promotes the degradation of AGPS, phosphorylation kinase TrkA aberrantly activated in prostate cancer and facilitates MDM2 ubiquitinate AGPS. TrkA inhibitor Larotrectinib could reactivate peroxisome pathway and sensitive prostate cancer cells to ML210. The combined administration of ML210 and Larotrectinib could significantly ablate the progression of prostate cancer.The model was created by Pro Procreate software and BioRender website (www.biorender.com)